Cartesian Therapeutics, Inc. Share Price & Technical Analysis
RNAC · $6.89 (+0.58%)
Healthcare / Biotechnology
$6.89
+0.58%
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases…
Price chart
Seasonality
Jun has 2 positive and 3 negative years (last 5 years shown)
-9% return in Jun, -7% avg return in past 3 year Jun month.
-1% return in 2026, -17% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -7% | 10% | -16% | 0% | 21% | -9% | – | – | – | – | – | – | -1% |
| 25 | 7% | -1% | -28% | -10% | -20% | 7% | 24% | -20% | 1% | -20% | -7% | -3% | -69% |
| 24 | 4% | 2% | -14% | 13% | 56% | -23% | -38% | -14% | 18% | 21% | -7% | -4% | 13% |
| 23 | 57% | -8% | -15% | -13% | 0% | -4% | -3% | 15% | -15% | 20% | 12% | -41% | 5% |
| 22 | -24% | -27% | -34% | -38% | 13% | 30% | 23% | 18% | -11% | -5% | -18% | -14% | -87% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Uptrend
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$173.06M
P/E ratio
—
52W high
$15.57
52W low
$5.60
Volume
11,431
Beta
0.78
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹35,920
Abbott Laboratories Cede…
₹33,540
Eli Lilly And Company Ce…
₹30,700
Unitedhealth Group Inc C…
₹18,590
₹7,059
Frequently asked questions
- What is Cartesian Therapeutics, Inc. share price today?
- Cartesian Therapeutics, Inc. (RNAC) last traded around $6.89 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does RNAC have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for RNAC. Download the app for real-time alerts.
- How can I analyze Cartesian Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.